2007
Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice
Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-α by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Molecular Cancer Therapeutics 2007, 6: 2652-2663. PMID: 17913856, DOI: 10.1158/1535-7163.mct-06-0759.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAnimalsAntineoplastic AgentsBlotting, WesternCell ProliferationEpidermal Growth FactorErbB ReceptorsGefitinibGene DosageHumansLung NeoplasmsMaleMiceMice, NudePhosphorylationPurinesQuinazolinesReverse Transcriptase Polymerase Chain ReactionTransforming Growth Factor alphaXenograft Model Antitumor AssaysConceptsTumor-associated endothelial cellsEpidermal growth factor receptorTreatment of miceLung cancerEpidermal growth factorNCI-H441Endothelial cellsLung tumorsLigand expressionNon-small cell lung cancerExpression of EGFTumor cellsEGFR tyrosine kinase inhibitorsEGFR tyrosine kinase inhibitor gefitinibGrowth factorReceptor tyrosine kinase inhibitionTyrosine kinase inhibitor gefitinibLymph node metastasisCell lung cancerEGF receptor tyrosine kinase inhibitionLungs of miceHuman lung cancer cellsHuman lung cancerPrimary tumor growthTyrosine kinase inhibitors
2006
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program
Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 2006, 53: 331-337. PMID: 16797779, DOI: 10.1016/j.lungcan.2006.04.013.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerExpanded Access ProgramCell lung cancerLung cancerRecurrent advanced non-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibNumerous clinical guidelinesSafety of gefitinibBest supportive careCommon adverse eventsPartial response ratePoor performance statusRetrospective chart reviewMajority of patientsTyrosine kinase inhibitor gefitinibFavorable toxicity profileAccess programKinase inhibitor gefitinibPrevious chemotherapyStable diseaseSubsequent chemotherapyChemonaive patientsAdverse eventsChart review
2004
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. Journal Of Clinical Oncology 2004, 22: 777-784. PMID: 14990632, DOI: 10.1200/jco.2004.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleGefitinibGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingProbabilityPrognosisQuinazolinesReference ValuesSurvival AnalysisTreatment OutcomeConceptsChemotherapy-naive patientsAdvanced NSCLCLung cancerAdvanced non-small cell lung cancerResponse rateNon-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibEnd pointUnresectable stage IIICycles of chemotherapyEfficacy end pointPhase II trialFirst-line gemcitabineTyrosine kinase inhibitor gefitinibPhase I trialCell lung cancerUnexpected adverse eventsMedian survival timeKinase inhibitor gefitinibFurther preclinical testingDaily gefitinibFavorable tolerabilityII trialPlacebo groupAdverse events
2003
Targeting the epidermal growth factor receptor: prognostic and clinical implications
Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. European Journal Of Cancer Supplements 2003, 1: 9-15. DOI: 10.1016/s1359-6349(03)80015-0.Peer-Reviewed Original ResearchEpidermal growth factor receptorGrowth factor receptorEGFR tyrosine kinase inhibitor gefitinibFactor receptorTyrosine kinase inhibitor gefitinibCell lung cancerKinase inhibitor gefitinibPerformance statusClinical responseSkin toxicityPrognostic valueDisease characteristicsLung cancerSurrogate markerClinical trialsNovel anticancer agentsInhibitor gefitinibClinical implicationsGefitinibAntitumour activityBiological markersPromising targetExpression levelsTumorigenic processAnticancer agents